These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 5962711

  • 1. [The results of treatment with minor drugs, i.e. kanamycin, ethionamide and cycloserine, for severe pulmonary tuberculosis patients discharging bacilli resistant to all the three major drugs].
    Matsumoto M, Izumi K, Kamima H, Hirose H, Saito M.
    Kekkaku; 1966 Jan; 41(1):39-46. PubMed ID: 5962711
    [No Abstract] [Full Text] [Related]

  • 2. Therapeutic effect of minor antituberculosis drugs on advanced pulmonary tuberculosis.
    Ando M.
    Nagoya J Med Sci; 1967 Jan; 29(3):261-70. PubMed ID: 6074943
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
    Prasad R, Verma SK, Sahai S, Kumar S, Jain A.
    Indian J Chest Dis Allied Sci; 2006 Jan; 48(3):183-6. PubMed ID: 18610675
    [Abstract] [Full Text] [Related]

  • 4. [Cases of pulmonary tuberculosis in which kanamycin-resistant tubercle bacilli did not appear even after a long-term administration of kanamycin. Some consideration on the interpretation of drug resistance tests].
    Tsukamura M.
    Kekkaku; 1971 Oct; 46(10):405-8. PubMed ID: 4112456
    [No Abstract] [Full Text] [Related]

  • 5. [Primary drug resistance of Mycobacterium tuberculosis to 2d line preparations].
    Fedotova ZN, Gur'ian IE, Kochetov BI.
    Probl Tuberk; 1972 Oct; 50(11):21-4. PubMed ID: 4630564
    [No Abstract] [Full Text] [Related]

  • 6. [Evaluation of the therapeutic effects of secondary antitubercular agents].
    Watanabe S, Nosaki M, Iwasaki M, Hamano S, Furuya Y.
    Iryo; 1966 Mar; 20(3):251-6. PubMed ID: 5965119
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of kanamycin in a triple regimen of kanamycin, cycloserine and ethionamide in the treatment of far-advanced cases of pulmonary tuberculosis with tubercle bacilli resistant to primary drugs.
    Oka S, Motomiya M, Kato S, Sato H, Fujimoto M.
    Sci Rep Res Inst Tohoku Univ Med; 1967 Apr; 14(1):91-3. PubMed ID: 4968094
    [No Abstract] [Full Text] [Related]

  • 8. [Treatment of chronic destructive forms of pulmonary tuberculosis with drugs of the second series in different combinations].
    Mamolat AS, Bialik IB.
    Probl Tuberk; 1969 Apr; 47(6):23-8. PubMed ID: 4311969
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical problems of resistance to secondary antitubercular agents].
    Baba H, Takahashi R, Nakai T, Torii R, Yo I.
    Iryo; 1966 Mar; 20(3):230-40. PubMed ID: 5964830
    [No Abstract] [Full Text] [Related]

  • 10. [Resistance of tubercle bacilli to cycloserine, viomycin and ethionamide in patients suffering from pulmonary tuberculosis].
    Srednicka-Zajac D, Mysakowska H, Szarewicz-Adamczyk W, Litwin B.
    Ann Univ Mariae Curie Sklodowska Med; 1967 Mar; 22():71-8. PubMed ID: 4308440
    [No Abstract] [Full Text] [Related]

  • 11. [Observations on antituberculous drug-resistance among pulmonary tuberculosis patients at the National Sanatoria in Kyushu district. 3. The secondary anti-tuberculosis agents (kanamycin, cycloserine, ethionamide)].
    Yamaguchi S.
    Iryo; 1968 Oct; 22(10):1115-9. PubMed ID: 5715475
    [No Abstract] [Full Text] [Related]

  • 12. [Therapeutic effects of secondary antitubercular agents at our hospital].
    Nakayama K, Hayashida M, Ishihara M, Ijichi F, Obata Y.
    Iryo; 1966 Mar; 20(3):257-63. PubMed ID: 5964832
    [No Abstract] [Full Text] [Related]

  • 13. The treatment of drug resistant chronic pulmonary tuberculosis with new tuberculostatics.
    Zierski M.
    Bull Int Union Tuberc; 1968 Dec; 41():194-200. PubMed ID: 4303863
    [No Abstract] [Full Text] [Related]

  • 14. On the treatment of primary tuberculosis in tender age (0-5 years) with resistomycin, cycloserine, and ethionamid.
    Dobrev P, Slaveykova A, Lankova D.
    Nauchni Tr Vissh Med Inst Sofiia; 1966 Dec; 45(5):37-42. PubMed ID: 4228990
    [No Abstract] [Full Text] [Related]

  • 15. [Autonomous treatment of pulmonary tuberculosis with delayed-action drugs].
    Pannain M, Tarantino AB, Mac Dowell A, Costa JA, Cunha JM, Pantoja W.
    Rev Bras Med; 1967 Aug; 24(8):664-8. PubMed ID: 5603007
    [No Abstract] [Full Text] [Related]

  • 16. [Evolution of antibiograms of bacilli persisting under treatment in the sanatorium].
    Marion L.
    Rev Tuberc Pneumol (Paris); 1967 Aug; 31(6):785-808. PubMed ID: 4317451
    [No Abstract] [Full Text] [Related]

  • 17. [Results of treatment with a combined 3-drug regimen of secondary drugs in chronic cavernous pulmonary tuberculosis. A study under auspices of the International Union against Tuberculosis].
    Zierski M, Zacara A, Woźniak S.
    Gruzlica; 1968 Sep; 36(9):809-18. PubMed ID: 4882450
    [No Abstract] [Full Text] [Related]

  • 18. Ethionamide, pyrazinamide and cycloserine in drug resistant cases.
    Narang RK, Singh SK.
    Indian J Chest Dis; 1973 Jan; 15(1):16-20. PubMed ID: 4695462
    [No Abstract] [Full Text] [Related]

  • 19. [Pulmonary tuberculosis with early verification].
    Anzalone M, Franco M, Rangoni R, Rossi F, Simonetti M.
    G Pneumol; 1970 Dec; 14(4):209-27. PubMed ID: 5526259
    [No Abstract] [Full Text] [Related]

  • 20. [Therapy of pulmonary tuberculosis with reserve drugs in the light of our personal observations].
    Kochnowski G.
    Wiad Lek; 1970 Jan 01; 23(1):9-13. PubMed ID: 4312765
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.